NZ239921A - Substituted xanthine derivatives; medicaments. - Google Patents

Substituted xanthine derivatives; medicaments.

Info

Publication number
NZ239921A
NZ239921A NZ239921A NZ23992191A NZ239921A NZ 239921 A NZ239921 A NZ 239921A NZ 239921 A NZ239921 A NZ 239921A NZ 23992191 A NZ23992191 A NZ 23992191A NZ 239921 A NZ239921 A NZ 239921A
Authority
NZ
New Zealand
Prior art keywords
medicaments
xanthine derivatives
substituted xanthine
substituted
derivatives
Prior art date
Application number
NZ239921A
Inventor
Derek Richard Buckle
David Glynn Smith
Ashley Edward Fenwick
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of NZ239921A publication Critical patent/NZ239921A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ239921A 1990-09-26 1991-09-24 Substituted xanthine derivatives; medicaments. NZ239921A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020959A GB9020959D0 (en) 1990-09-26 1990-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
NZ239921A true NZ239921A (en) 1993-12-23

Family

ID=10682788

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ239921A NZ239921A (en) 1990-09-26 1991-09-24 Substituted xanthine derivatives; medicaments.

Country Status (12)

Country Link
EP (1) EP0550570A1 (en)
JP (1) JPH06501251A (en)
KR (1) KR930702351A (en)
AU (1) AU653364B2 (en)
CA (1) CA2092430A1 (en)
GB (1) GB9020959D0 (en)
IE (1) IE913350A1 (en)
MX (1) MX9101237A (en)
NZ (1) NZ239921A (en)
PT (1) PT99062A (en)
WO (1) WO1992005175A1 (en)
ZA (1) ZA917610B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098846A1 (en) * 1990-12-21 1992-06-22 David G. Smith Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
EP0825993A1 (en) * 1995-05-19 1998-03-04 Chiroscience Limited Xanthines and their therapeutic use
MA24682A1 (en) 1997-10-23 1999-07-01 Smithkline Beecham Corp NEW POLYMORPHIC FORMS OF CIPAMFYLLINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
JP2004502690A (en) 2000-07-04 2004-01-29 ノボ　ノルディスク　アクティーゼルスカブ Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
KR20030014394A (en) * 2000-07-04 2003-02-17 노보 노르디스크 에이/에스 Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1509525T1 (en) 2002-05-31 2006-12-31 Schering Corp Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
US7495004B2 (en) 2002-06-17 2009-02-24 Glaxo Group Limited Purine derivatives as liver X receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ATE363483T1 (en) 2003-07-31 2007-06-15 Schering Corp METABOLITE OF A XANTHINE PHOSPHODIESTERASE-5 INHIBITOR AND DERIVATIVES THEREOF SUITABLE FOR THE TREATMENT OF ERECTION DISORDERS
WO2005058898A2 (en) * 2003-12-16 2005-06-30 Ranbaxy Laboratories Limited Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (en) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
DE102004037554A1 (en) 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkylthio-xanthines, process for their preparation and their use as medicaments
DE102004039507A1 (en) 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkoxi-xanthines, process for their preparation and their use as medicaments
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
NO347644B1 (en) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorphs
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (en) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
KR101985384B1 (en) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005775A1 (en) * 1987-01-30 1988-08-11 Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H. Novel xanthine derivatives
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
AU9024591A (en) * 1990-10-25 1992-05-26 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders

Also Published As

Publication number Publication date
IE913350A1 (en) 1992-04-08
JPH06501251A (en) 1994-02-10
PT99062A (en) 1992-08-31
WO1992005175A1 (en) 1992-04-02
MX9101237A (en) 1992-05-04
CA2092430A1 (en) 1992-03-27
AU8541391A (en) 1992-04-15
ZA917610B (en) 1992-09-30
KR930702351A (en) 1993-09-08
GB9020959D0 (en) 1990-11-07
EP0550570A1 (en) 1993-07-14
AU653364B2 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
NZ239921A (en) Substituted xanthine derivatives; medicaments.
ZA919660B (en) Alpha-oxoacetamide derivatives.
OA09205A (en) 3-substituted-2-oxindole derivatives.
EP0440950A3 (en) Halogenallyl-azolyl derivatives
EP0470466A3 (en) Halogenalkyl-azolyl derivatives
PH30977A (en) Hiv-inhibiting benzene-acetamide derivatives.
EP0436333A3 (en) Azaoxindole derivatives
OA08741A (en) N-phenylpyrazol derivatives.
EP0438690A3 (en) Substituted pyrazolin derivatives
ZA929934B (en) Heterocyclic derivatives.
ZA928742B (en) Heterocyclic derivatives.
EP0485984A3 (en) Diarylmethoxypiperidine derivatives
GR3017794T3 (en) Novel neplanocin derivatives.
OA09716A (en) Benzoxaiole derivatives.
GB9007569D0 (en) Carbo-nucleoside derivatives
EP0440949A3 (en) Halogenallyl-azolyl derivatives
EP0453883A3 (en) 2-amino-4-trichloropyridine derivatives
AP9100308A0 (en) Carboxymethylcyclopropane derivatives
ZA926417B (en) New heterocyclic derivatives.
GB2249094B (en) Hetero-imidazodiazepine derivatives
IE901754L (en) Heterocyclylalkanol derivatives.
IE900323L (en) Aminoalkoxyphenyl derivatives.
GB9006772D0 (en) 4-piperidinyl-ergoline derivatives
ZA917697B (en) Phenylpyridinol derivatives as medicaments
IE880985L (en) Pyrazole derivatives.